G

GSK

Develops medicines, vaccines, and consumer health

RE & Operations – Senior Major Incident Manager & Service Desk Assurance

Full-TimeUpdated
No salary listed
Expert
Bachelor's, Master's
Philadelphia, PA, USA+1 moreMore locations: Durham, NC, USA
HybridHybrid role with regular on-site meetings; remote work when appropriate. Occasional extended hours or on-call shifts may be required.
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • A Bachelor's or Master's degree in a relevant field, such as Computer Science, IT, or a business discipline, or equivalent experience.
  • ITIL v4 certification is required.
  • At least 10 years of experience in service management or service desk assurance within a large, complex, global organization.
  • Experience governing an outsourced service desk against SLAs, XLAs, and experience metrics while driving continuous improvement.
  • Experience designing and refreshing SLAs and XLAs to sustain continuous stretch and improvement.
  • Experience running a structured voice-of-the-customer to improvement cycle.
  • Experience driving Service Desk modernization through AI, automation, and shift-left initiatives, with demonstrable improvements in adoption, colleague experience, and operational performance.
  • Experience working with strategic partners and managed service providers while retaining in-house governance.
  • Experience owning the end-to-end colleague experience of the Service Desk, including retaining accountability for outcomes when issues escalate from L1 to L2 and ensuring L2 delivers the required resolution.
Responsibilities
  • Manage the outsourced Tech Service Desk provider to agreed SLAs, XLAs, and quality expectations, holding the provider accountable for outcomes.
  • Assure service quality and delivery discipline, driving improvements where performance or experience falls short.
  • Own the end-to-end colleague experience of the Service Desk beyond the L1 interaction; retain accountability for escalated issues and ensure L2 resolves them, escalating to L2 service owners where appropriate.
  • Drive the refresh of SLAs, XLAs, and measures to ensure continuous stretch and improvement.
  • Set, monitor, and govern service standards and improvement plans across internal and provider teams.
  • Ensure a robust voice-of-the-customer feedback-to-improvement cycle, using experience data such as XLA and CSAT to shape service change.
  • Define and govern service standards, quality expectations, and operational governance artefacts.
  • Maintain the controls, evidence, and documentation needed to keep the Service Desk operation audit-ready for internal and external audits.
  • Ensure compliance of products owned by and directly supporting the Service Desk, such as Smart IVR.
  • Own and drive the Service Desk modernization agenda with the outsourced provider, Automation Acceleration Hub, and enabling product teams to increase the use of AI and automation across operations.
  • Expand knowledge-enabled resolution, intelligent self-service, automation, and effective deflection to advance shift left while improving colleague experience and service efficiency.
  • Translate modernization opportunities into a prioritized roadmap with clear adoption, experience, and performance outcomes; hold partners accountable for delivery and realized benefits.
  • Ensure AI and automation are used responsibly, with appropriate security, compliance, human review, and change control before operational use.
Desired Qualifications
  • Experience in a regulated industry, such as pharmaceuticals, life sciences, financial services, or a similar sector.
  • Ability to balance control, compliance, pace, and agility while holding a provider accountable.
  • Strong SLA/XLA design, performance-management, and governance capability.
  • Strong documentation, standards, and process-design capability.
  • Ability to interpret service performance and experience data.
  • Practical AI fluency, applying Service Desk automation within security, compliance, and change guardrails.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.